SANTA CLARA, Calif., March 26, 2018 /PRNewswire/ --†Frost & Sullivan's latest analysis, Global Biologics MarketóCompanies-to-Action,
Frost & Sullivan's recent analysis provides a detailed profile of the top 10 global biopharmaceutical companies, including the top five products and pipelines by development phase. In addition, the study projects that the market will reach over $300 billion by 2022 at a compound annual growth rate (CAGR) of close to 10 percent.
For further information on this analysis, please visit: http://frost.ly/286
"To keep up with the growing demand for new and advanced therapies, companies are either adopting hybrid business models or indulging in partnerships or acquisition activities to attain technology proficiency as well as specific therapy expertise," said Aarti Chitale, Transformational Health Senior Research Analyst at Frost & Sullivan. "As a result, virtual pharmaceutical companies are coming to the fore by collaborating with bigger pharmaceutical players and providing specific services to these partners in terms of drug discovery, development, or manufacturing."
Strategic imperatives for the global biologics companies include:
"Alongside industry and academic research collaborations, companies are focusing on partnering with IT players such as IBM Watson Health, GE Healthcare Life Sciences, which provide technologically advanced solutions for conducting clinical trials and supporting complex drug manufacturing processes," observed Chitale. "While these collaborations are expected to mitigate certain manufacturing difficulties and create integrated business models, higher manufacturing costs are likely to affect the pricing of these molecules, thus impacting the adoption rate, especially across emerging markets with inadequate reimbursement facilities."
Global Biologics MarketóCompanies-to-Action is part of Frost & Sullivan's Transformational Health Growth Partnership Services program.
About Frost & SullivanFor over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion
Global Biologics MarketóCompanies-to-ActionMD83_52
Contact:Mariana FernandezCorporate Communications Ė North AmericaP: +1 (210) 348 1012E: Mariana.Fernandez@frost.com
LinkedIn: Transform Health
View original content:http://www.prnewswire.com/news-releases/global-biologics-market-to-surpass-300-billion-by-2022-with-accelerated-new-launches-in-oncology-300619374.html
SOURCE Frost & Sullivan
Subscribe to our Free Newsletters!
Bubonic plague is an infectious disease caused by the bacteria Yersinia pestis present in rodents ...
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...View All